0R15 7941.0 -0.9233% 0R1E 7597.0 3.5437% 0M69 None None% 0R2V 182.6 3.0183% 0QYR 1369.0 -0.9407% 0QYP 409.9595 -0.4953% 0LCV 141.835 -0.3268% 0RUK None None% 0RYA 1604.0 -3.3153% 0RIH 170.0 -1.0477% 0RIH 169.0619 -0.5518% 0R1O 192.5 10152.996% 0R1O None None% 0QFP None None% 0M2Z 304.7 0.7273% 0VSO None None% 0R1I None None% 0QZI 472.0 0.6397% 0QZ0 220.0 0.0% 0NZF None None%
Last update at 2024-05-09T09:43:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -410.42200M | -215.74000M | -189.73400M | -141.10500M | -86.65500M |
| Minority interest | -0.44900M | -27.60700M | 34.83M | 24.89M | 23.26M |
| Net income | -410.13900M | -227.65800M | -194.56300M | -144.37900M | -74.80500M |
| Selling general administrative | 92.17M | 89.30M | 50.02M | 39.21M | 30.91M |
| Selling and marketing expenses | 43.93M | 37.83M | 11.33M | 13.72M | 17.74M |
| Gross profit | 115.31M | 97.89M | 39.46M | 44.74M | 70.17M |
| Reconciled depreciation | 8.66M | 7.19M | 6.06M | 4.94M | 3.59M |
| Ebit | -409.77000M | -336.45800M | -188.94700M | -145.01900M | -69.83200M |
| Ebitda | -401.10600M | -329.26800M | -182.88600M | -135.13300M | -66.24200M |
| Depreciation and amortization | 8.66M | 7.19M | 6.06M | 9.89M | 3.59M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -409.77000M | -336.45800M | -188.94700M | -145.01900M | -92.64100M |
| Other operating expenses | 834.10M | 684.45M | 424.64M | 349.91M | 306.75M |
| Interest expense | 0.65M | 0.59M | 0.79M | 1.03M | 1.01M |
| Tax provision | -0.28300M | 11.92M | 4.83M | 3.27M | 3.96M |
| Interest income | 9.60M | 2.08M | 3.24M | 4.94M | 5.98M |
| Net interest income | 8.95M | 1.48M | 2.45M | 3.91M | 4.97M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.28300M | 11.92M | 4.83M | 3.27M | 3.96M |
| Total revenue | 426.41M | 356.13M | 227.98M | 204.89M | 214.11M |
| Total operating expenses | 523.00M | 426.21M | 236.12M | 189.76M | 162.81M |
| Cost of revenue | 311.10M | 258.23M | 188.52M | 160.15M | 143.94M |
| Total other income expense net | -0.65200M | 120.72M | -0.78700M | 3.91M | 5.99M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -360.38600M | -167.04100M | -115.51700M | -103.67900M | -71.28600M |
| Net income applicable to common shares | -360.83500M | -194.64800M | -125.73000M | -106.02400M | -74.80500M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 1029.44M | 1372.66M | 724.12M | 465.12M | 532.12M |
| Intangible assets | - | 0.16M | 0.23M | 0.28M | 0.35M |
| Earning assets | - | - | - | - | - |
| Other current assets | 152.20M | 164.62M | 75.80M | 83.65M | 57.28M |
| Total liab | 392.57M | 333.15M | 205.17M | 152.22M | 119.86M |
| Total stockholder equity | 610.37M | 986.89M | 484.12M | 288.01M | 389.00M |
| Deferred long term liab | - | - | 1.17M | 0.18M | - |
| Other current liab | 282.79M | 17.19M | 0.37M | 0.45M | 59.30M |
| Common stock | 86.48M | 86.45M | 72.77M | 66.69M | 66.66M |
| Capital stock | 86.48M | 86.45M | 72.77M | 66.69M | 66.66M |
| Retained earnings | -971.48100M | -610.32800M | -415.59100M | -289.73400M | -183.00400M |
| Other liab | 15.37M | 14.33M | 13.27M | 8.67M | 7.07M |
| Good will | - | 3.38M | 3.31M | 3.11M | 3.19M |
| Other assets | 31.11M | 27.41M | 18.15M | 19.40M | 3.11M |
| Cash | 313.28M | 377.54M | 235.63M | 121.16M | 86.04M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 353.90M | 311.66M | 158.40M | 113.10M | 85.48M |
| Current deferred revenue | - | 226.38M | 123.63M | 85.48M | - |
| Net debt | -289.97800M | -343.47600M | -199.92000M | -88.07400M | -59.29700M |
| Short term debt | - | 26.91M | 2.79M | 3.22M | 214.91M |
| Short long term debt | 0.00000M | 26.91M | - | - | 0.00000M |
| Short long term debt total | 23.30M | 34.07M | 35.71M | 33.08M | 26.74M |
| Other stockholder equity | 1495.37M | 1510.77M | 826.93M | 511.06M | 525.17M |
| Property plant equipment | 84.67M | 53.15M | 32.19M | 26.37M | 16.62M |
| Total current assets | 839.89M | 1212.08M | 530.74M | 317.02M | 370.54M |
| Long term investments | - | - | - | 98.94M | 138.32M |
| Net tangible assets | 610.37M | 983.35M | 480.58M | 284.62M | 385.46M |
| Short term investments | 317.72M | 634.16M | 199.55M | 96.01M | 214.91M |
| Net receivables | 97.99M | 147.73M | 64.44M | 77.35M | 51.23M |
| Long term debt | 18.10M | 0.00000M | 26.86M | 26.82M | 26.74M |
| Inventory | 56.69M | 35.76M | 19.77M | 16.21M | 12.31M |
| Accounts payable | 71.11M | 41.18M | 31.61M | 23.96M | 25.62M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | -26.28100M | -23.35200M | -19.82600M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 72.77M | 66.69M | 66.66M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 333.46M | 639.00M | 203.06M | 113.48M | 216.27M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 189.56M | 160.59M | 193.38M | 148.10M | 161.58M |
| Capital lease obligations | 5.20M | 7.16M | 8.85M | 6.26M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 296.59M | -275.49400M | -103.53500M | 118.90M | 50.12M |
| Change to liabilities | 30.32M | 20.64M | 7.49M | -2.37300M | 1.02M |
| Total cashflows from investing activities | 296.59M | -306.32000M | -125.44100M | 119.03M | 43.75M |
| Net borrowings | -9.17000M | -0.57900M | -0.57900M | -0.11600M | -4.62700M |
| Total cash from financing activities | -82.76300M | 650.03M | 296.43M | -1.49300M | -8.23100M |
| Change to operating activities | 64.04M | 63.46M | 30.10M | 22.96M | 7.18M |
| Net income | -360.38600M | -167.04100M | -115.51700M | -103.67900M | -71.28600M |
| Change in cash | -64.26400M | 141.91M | 114.47M | 35.12M | 0.77M |
| Begin period cash flow | 377.54M | 235.63M | 121.16M | 86.04M | 85.27M |
| End period cash flow | 313.28M | 377.54M | 235.63M | 121.16M | 86.04M |
| Total cash from operating activities | -268.59900M | -204.22300M | -62.06600M | -80.91200M | -32.84700M |
| Issuance of capital stock | 0.17M | 717.32M | 318.93M | 0.25M | 3.87M |
| Depreciation | 8.66M | 7.19M | 6.06M | 4.94M | 3.59M |
| Other cashflows from investing activities | - | -15.00000M | -105.86100M | 127.59M | 50.12M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -21.21300M | -16.00200M | -3.62300M | -4.21500M | -0.55700M |
| Change to account receivables | -14.45100M | -35.63400M | -4.69300M | -0.27100M | -0.48600M |
| Sale purchase of stock | -48.08400M | -27.30900M | -12.90400M | -0.34600M | -5.45100M |
| Other cashflows from financing activities | -7.93000M | -39.98200M | -9.59600M | 25.52M | 23.35M |
| Change to netincome | 24.85M | -49.26700M | 28.29M | 3.87M | 31.13M |
| Capital expenditures | 36.66M | 16.76M | 19.58M | 8.56M | 6.36M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 58.70M | 32.46M | 29.27M | 16.11M | 6.96M |
| Stock based compensation | 30.59M | 41.99M | 19.64M | 11.59M | 10.13M |
| Other non cash items | -6.16700M | -3.68300M | -2.07700M | 0.39M | 17.76M |
| Free cash flow | -305.26300M | -220.97900M | -81.64600M | -89.47700M | -39.21100M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (GBP) | Price (GBP) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HCM HUTCHMED China Ltd |
21.00 6.71% | 334.00 | - | - | 3.22 | 3.97 | 2.39 | -19.4252 |
| HLN Haleon PLC |
0.50 0.15% | 328.70 | 24.73 | 16.86 | 2.63 | 1.81 | 3.17 | 16.57 |
| HIK Hikma Pharmaceuticals PLC |
1.00 0.05% | 1974.00 | 33.45 | 11.14 | 1.45 | 2.32 | 1.76 | 8.98 |
| INDV Indivior PLC |
13.00 0.91% | 1435.00 | - | - | 1.60 | 48.69 | 1.17 | -4.7616 |
| HELD Hellenic Dynamics PLC |
-0.001 0.05% | 1.90 | - | - | - | 2.57 | -9.0325 |
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
Cheung Kong Center, Central, Hong Kong
| Name | Title | Year Born |
|---|---|---|
| Mr. Chi Keung To ACGI, B.Sc., BSc, M.B.A., MBA | Exec. Chairman | 1952 |
| Dr. Weiguo Su B.Sc., Ph.D. | CEO, Chief Scientific Officer & Exec. Director | 1957 |
| Mr. Chig Fung Cheng BEc, CA | CFO & Exec. Director | 1967 |
| Ms. Edith Shih C.S., CGP, FCS, M.A., P.E., BSE, EdM, Solicito | Company Sec. & Non-Exec. Director | 1952 |
| Dr. Karen Jane Atkin | Exec. VP & COO | 1966 |
| Mr. Kin Hung Lee M.B.A. | Sr. VP of Corp. Fin. & Devel. | 1977 |
| Mr. Charles George Rupert Nixon | Group Gen. Counsel | 1970 |
| Ms. Selina Zhang | Sr. VP of Global HR | NA |
| Dr. Qingmei Wang Ph.D. | Sr. VP of Bus. Devel. & Strategic Alliances | 1963 |
| Mr. Hong Chen | Sr. VP & Chief Commercial Officer- China | 1970 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
UK 
AU
CA
US
NZ
Please wait processing your request...